11/8
04:12 pm
aort
Artivion Inc (AORT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances [Yahoo! Finance]
Low
Report
Artivion Inc (AORT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances [Yahoo! Finance]
11/8
11:17 am
aort
Artivion, Inc. (NYSE: AORT) had its price target raised by analysts at Oppenheimer Holdings Inc. from $30.00 to $32.00. They now have an "outperform" rating on the stock.
Low
Report
Artivion, Inc. (NYSE: AORT) had its price target raised by analysts at Oppenheimer Holdings Inc. from $30.00 to $32.00. They now have an "outperform" rating on the stock.
11/7
04:05 pm
aort
Artivion Reports Third Quarter 2024 Financial Results
Low
Report
Artivion Reports Third Quarter 2024 Financial Results
11/5
04:15 pm
aort
Artivion to Participate in Upcoming Investor Conferences
Medium
Report
Artivion to Participate in Upcoming Investor Conferences
10/24
04:15 pm
aort
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results
Low
Report
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results
10/23
01:47 pm
aort
Artivion started at market outperform by JMP, stent graft devices cited [Seeking Alpha]
Low
Report
Artivion started at market outperform by JMP, stent graft devices cited [Seeking Alpha]
10/23
07:35 am
aort
Artivion, Inc. (NYSE: AORT) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $33.00 price target on the stock.
Medium
Report
Artivion, Inc. (NYSE: AORT) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $33.00 price target on the stock.
10/10
04:10 pm
aort
Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
Low
Report
Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
9/27
08:08 am
aort
Artivion, Inc. (NYSE: AORT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
Medium
Report
Artivion, Inc. (NYSE: AORT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
9/26
10:12 am
aort
Those who invested in Artivion (NYSE:AORT) a year ago are up 61% [Yahoo! Finance]
Low
Report
Those who invested in Artivion (NYSE:AORT) a year ago are up 61% [Yahoo! Finance]
9/13
10:09 am
aort
Artivion, Inc. (NYSE: AORT) had its price target raised by analysts at Stifel Nicolaus from $28.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Artivion, Inc. (NYSE: AORT) had its price target raised by analysts at Stifel Nicolaus from $28.00 to $30.00. They now have a "buy" rating on the stock.
9/2
10:29 am
aort
Is Now An Opportune Moment To Examine Artivion, Inc. (NYSE:AORT)? [Yahoo! Finance]
Medium
Report
Is Now An Opportune Moment To Examine Artivion, Inc. (NYSE:AORT)? [Yahoo! Finance]
8/30
06:19 am
aort
Should You Invest in Artivion (AORT)? [Yahoo! Finance]
Low
Report
Should You Invest in Artivion (AORT)? [Yahoo! Finance]
8/16
10:59 am
aort
Organ and Tissue Transplantation Strategic Research Report 2023-2030: Rising Focus on Immunosuppressive Therapies Strengthens Business Case for Post-Transplant Care [Yahoo! Finance]
Low
Report
Organ and Tissue Transplantation Strategic Research Report 2023-2030: Rising Focus on Immunosuppressive Therapies Strengthens Business Case for Post-Transplant Care [Yahoo! Finance]